5U9 Stock Chart & Stats
€0.01
>-€0.01(-16.67%)
At close: 4:00 PM EDT
€0.01
>-€0.01(-16.67%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.02
Previous CloseN/A
Volume0.00
Average Volume (3M)50.43K
Market Cap
€1.30M
Enterprise Value€3.21M
Total Cash (Recent Filing)€605.05K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.78
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding407,715,850
10 Day Avg. Volume1,050
30 Day Avg. Volume50,432
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.86
Price to Sales (P/S)12.22
P/FCF Ratio-1.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe company is generating measurable top-line growth, indicating some customer demand and commercial traction in its wellness product portfolio. If revenue expansion persists, it could provide a larger base for operating leverage and support broader product commercialization over the next several quarters.
Debt-Free Balance SheetA debt-free balance sheet reduces interest obligations, refinancing exposure, and lender-imposed constraints. This gives management greater flexibility to direct available resources toward product development and commercialization, although the benefit is limited by the company’s substantial operating cash burn.
Defined Product PlatformThe business has a clearly defined platform centered on extracting, standardizing, and formulating Amanita-derived ingredients for consumer wellness use. A focused product strategy can support consistent development priorities and a coherent commercialization pathway as the company expands its offering.
Bears Say
Severe UnprofitabilityNegative gross margin means current sales are not covering product-level costs, while the extremely negative net margin shows that operating expenses remain far above the revenue base. Without substantial improvement in pricing, costs, or scale, earnings power is unlikely to become durable.
Persistent Cash BurnHeavy operating and free-cash-flow losses indicate that the business is consuming cash rather than funding its own activities. Continued burn can constrain investment in product commercialization and increase reliance on additional financing, even though the company currently reports no debt.
Shrinking Equity BaseThe sharp reduction in equity reflects accumulated losses and erosion of the capital base supporting the business. A smaller equity cushion reduces resilience against further losses and may limit strategic flexibility, while future funding could dilute existing shareholders if new equity is required.
Psyched Wellness News
5U9 FAQ
What was Psyched Wellness’s price range in the past 12 months?
Psyched Wellness lowest stock price was <€0.01 and its highest was €0.02 in the past 12 months.
What is Psyched Wellness’s market cap?
Psyched Wellness’s market cap is €1.30M.
When is Psyched Wellness’s upcoming earnings report date?
Psyched Wellness’s upcoming earnings report date is Apr 01, 2027 which is in 151 days.
How were Psyched Wellness’s earnings last quarter?
Psyched Wellness released its earnings results on Jul 24, 2026. The company reported -€0.003 earnings per share for the quarter.
Is Psyched Wellness overvalued?
According to Wall Street analysts Psyched Wellness’s price is currently Overvalued.
Does Psyched Wellness pay dividends?
Psyched Wellness does not currently pay dividends.
What is Psyched Wellness’s EPS estimate?
Psyched Wellness’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Psyched Wellness have?
Psyched Wellness has 407,715,850 shares outstanding.
What happened to Psyched Wellness’s price movement after its last earnings report?
Psyched Wellness reported an EPS of -€0.003 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Psyched Wellness?
Currently, no hedge funds are holding shares in DE:5U9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Psyched Wellness
Psyched Wellness Ltd. operates as a health supplements enterprise, specializing in the production and distribution of artisanal medicinal mushrooms and their associated consumer packaged goods. A prominent offering is their Amanita Muscaria Tincture, formulated to soothe the body, alleviate physical discomfort, reduce stress, ease muscular tension, and promote restorative sleep. The company, established in 2019, was initially known as Duncan Park Holdings Corporation before officially adopting the name Psyched Wellness Ltd. in July 2020. Its headquarters are situated in Toronto, Canada.
Technical Analysis
―
Jamieson Wellness Inc
―
Happy Belly Food Group
―
Happy Supplements Inc.
―
Cult Food Science Corp.
―